EmphyCorp has been granted Orphan Drug status by the FDA to develop N115 for the treatment of Cystic Fibrosis. Cystic Fibrosis is a genetic disease afflicting nearly 30,000 persons in the United States and Canada and nearly 250,000 worldwide.

It is the most common life-shortening genetic disease in the white population, occurring in the USA in about 1/3,300 white births, in about 1/15,300 black births, and in about 1/32,000 Asian-American births. Fifty percent of CF patients present with pulmonary manifestations, usually chronic cough and wheezing associated with recurrent or chronic pulmonary infections.

Cough is the most troublesome complaint, often accompanied by sputum, gagging, vomiting, and disturbed sleep.

Early symptoms include inflammation, shortness of breath (dyspnea), Hypoxemia, fatigue, low SaO2,, low synthesis of nasal nitric oxide and coughing.

The ability to up regulate the synthesis of Nitric oxide is critical to treat lung infections.  N115 Nasal Spray with no known side effects increases the synthesis of nasal nitric oxide.